High-dose etoposide therapy for extensive small cell lung cancer: A cancer and leukemia group B study

Sharon D Luikart, K. J. Propert, C. R. Modeas, M. R. Green, M. C. Perry

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Twenty-one previously untreated patients with extensive small cell lung cancer were treated with etoposide, 400 mg/m2/day for 3 consecutive days. Myelosuppression was severe, with a treatment-related death rate of 28%. Five partial responses were achieved. High-dose etoposide as given in this study produced unacceptable toxicity and no complete responses.

Original languageEnglish (US)
Pages (from-to)533-534
Number of pages2
JournalCancer Treatment Reports
Volume71
Issue number5
StatePublished - 1987

Fingerprint Dive into the research topics of 'High-dose etoposide therapy for extensive small cell lung cancer: A cancer and leukemia group B study'. Together they form a unique fingerprint.

  • Cite this

    Luikart, S. D., Propert, K. J., Modeas, C. R., Green, M. R., & Perry, M. C. (1987). High-dose etoposide therapy for extensive small cell lung cancer: A cancer and leukemia group B study. Cancer Treatment Reports, 71(5), 533-534.